Amarin to Present REDUCE-IT Extreme-Risk Results and EPA Lp(a) Oxidation Findings
Amarin will present REDUCE-IT secondary analysis on March 29 in New Orleans demonstrating that icosapent ethyl reduces cardiovascular events in extreme-risk patients. On March 28, mechanistic in vitro data will show EPA inhibits lipoprotein(a) oxidation non-linearly.
1. REDUCE-IT Subgroup Analysis
Amarin-supported researchers will deliver oral findings from REDUCE-IT on March 29 at ACC Scientific Sessions, reporting that icosapent ethyl significantly reduces adverse cardiovascular events in extreme-risk cohorts. Detailed results will include event rates, relative risk reductions and patient characteristics.
2. In Vitro EPA Mechanistic Study
A mechanistic poster on March 28 will demonstrate that eicosapentaenoic acid inhibits lipoprotein(a) oxidation in vitro, exhibiting a non-linear inhibitory response at elevated Lp(a) concentrations. This data enhances understanding of EPA’s potential multifactorial cardiovascular benefits.
3. Commercial and Clinical Implications
These presentations could reinforce VASCEPA’s value proposition for patients with persistent risk despite statin therapy, potentially driving adoption in high-risk subgroups. Insights into mechanistic action may support discussions on label expansion and guideline inclusion.